

1st Half of Fiscal 2017 Financial Results

October 31, 2017

Isao Teshirogi, Ph.D. President and CEO



Agenda



Solving Social Issues to Accomplish Sustainable Growth

3. Addressing further societal needs to Accomplish Sustainable Growth

2. Maximizing Growth Drivers to Address Societal Needs -Contributing to a more vigorous society-

Beyond SGS2020

Prepare for the Further Sustainable Growth of the Shionogi Group

1. 1st Half FY2017 Financial Results and FY2017 Financial Forecasts

Exceed original FY2017 Revenue and Profit Targets

Growth with New Products

Toward Achievement of Updated SGS2020

- Growth Drivers Providing Revenue Base
 ✓ HIV franchise
- Next Growth Drivers
 - ✓ S-033188, Cefiderocol, Cymbalta[®], and ADHD franchise





1. 1st Half FY2017 Financial Results and FY2017 Financial Forecasts

1. 1st Half FY2017 Financial Results 2. FY2017 Financial Forecasts



Summary of 1H FY2017: Growth in Sales by New Products








* Royalty income from ViiV (HIV franchise) and AstraZeneca (Crestor[®])

S-O-N-G for you!

Summary of 1H FY2017: All Categories of Profit Reached Record Highs







S-O-N-G

Financial Results (Consolidated)

(Unit: B yen)

S-O-N-G

for you!

		FY2017				Υо	n Y
	Full year Forecasts	1H Forecasts*	1H Results	Progress vs 1H Forecasts (%)	1H Results	Change (%)	Change (B yen)
Sales	340.0	162.5	172.2	106.0	155.1	11.0	17.1
Operating income	112.5	46.0	55.8	121.2	44.3	25.9	11.5
Ordinary income	123.5	51.5	65.6	127.4	42.1	55.6	23.4
Profit attributable to owners of parent	92.0	38.5	50.3	130.7	31.2	61.3	19.1

Exchange Rate (average)	FY2017 Forecasts	FY2017 1H Results
USD (\$) – JPY (¥)	110.0	111.06
GBP (£) – JPY (¥)	140.0	143.59
EUR (€) – JPY (¥)	120.0	126.34



* The consolidated earnings forecasts announced on May 10, 2017 were written here, and the revisions to the forecasts were announced on Oct. 23, 2017.

Statements of Income (Consolidated)

(Unit: B yen)

S-O-N-G

for you!

		FY2	017		FY2016	Yo	n Y
	Full year Forecasts	1H Forecasts**	1H Results	Progress vs 1H Forecasts (%)	1H Results	Change (%)	Change (B yen)
Sales	340.0	162.5	172.2	106.0	155.1	11.0	17.1
(Royalty [*] income)	125.0	56.4	57.6	102.1	46.0	25.2	11.6
	22.5 [35.6]	24.9 [38.2]	23.0 [34.6]		25.0 [35.5]		
Cost of sales	76.5	40.5	39.7	98.0	38.7	2.5	1.0
Gross profit	263.5	122.0	132.5	108.6	116.4	13.8	16.1
	44.4	46.8	44.6		46.5		
SG&A expenses	151.0	76.0	76.7	101.0	72.1	6.4	4.6
Selling & administrative expenses	^{29.1} 99.0 ^{15.3}	^{29.8} 48.5 ^{16.9}	^{27.1} 46.6	96.2	^{29.3} 45.4 ^{17.2}	2.6	1.2
R&D expenses	52.0	27.5	30.1	109.5	26.7	12.9	3.4
Operating income	^{33.1} 112.5	^{28.3} 46.0	^{32.4} 55.8	121.2	^{28.6} 44.3	25.9	11.5
Non-operating income & expenses	P11.0	P5.5	P9.8	178.8	L2.1	-	12.0
Ordinary income	^{36.3} 123.5	^{31.7} 51.5	^{38.1} 65.6	127.4	^{27.2} 42.1	55.6	23.4



Note: Small numbers in red are percent of sales, and numbers inside of [] are percent of sales excluding royalties

* Royalty income from ViiV (HIV franchise) and AstraZeneca (Crestor®)

** The consolidated earnings forecasts announced on May 10, 2017 were written here, and the revisions were announced on Oct. 23, 2017.

Y on Y Comparison and Main Variation Factors (Statements of Income)

• Y on Y compari	ison	Main Variation Factors (Y on Y)
· · ·	(Unit: B yen)	 Sales Strong sales growth of strategic products
Sales	+17.1	 Increase of royalty income of HIV franchise from ViiV
Cost of sales	+1.0	 Received payments* from Roche regarding S-033188
Gross profit	+16.1	 SG&A expenses : Selling & administrative expenses : +1.2 B yen
Selling & administrative expenses	+1.2	 Advance investment for new products R&D expenses : +3.4 B yen
R&D expenses	+3.4	 Investment for global development of S-033188 Non-operating income & expenses
Operating income	+11.5	- Received dividend: Global sales growth of HIV franchise and
Non-operating Income & expenses	+12.0	dividend payment in accordance with the revised contract with ViiV
Ordinary income	+23.4	Main Variation Factors (vs 1H Forecasts**)
Decrease in profit	Growth in profit	 Cost of sales Cost of sales ratio
Progress vs 1H	Forecasts**	 Improved by 1.9%: Increase in royalty income Cost of sales ratio excluding royalty income***
Selling & administrative expenses	96.2%	 Improved by 3.6%: Received payments* from Roche regarding S-033188
R&D expenses	109.5%	 SG&A expenses: Total cost management Selling & administrative expenses : (1.9) B yen
Decrease in profit	Growth in profit	 R&D expenses : +2.6 B yen Investment for global development of S-033188



* Payments both for development progression events (such as study initiation/phase progression) and for obtaining successful results ** The consolidated earnings forecasts announced on May 10, 2017 were written here, and the revisions were announced on Oct. 23, 2017. *** Royalty income from ViiV (HIV franchise) and AstraZeneca (Crestor®)

Sales by Segments (Consolidated)

(Unit: B yen)

S-O-N-G


for you!

		FY	FY2016	Υо	n Y		
	Full year Forecasts	1H Forecasts*	1H Results	Progress vs. 1H forecasts (%)	1H Results	Change (%)	Change (B yen)
Prescription drugs	143.9	75.2	73.2	97.3	79.2	(7.6)	(6.0)
Overseas	25.4	12.3	12.2	99.0	15.3	(20.2)	(3.1)
Shionogi Inc.	12.0	6.0	6.0	101.3	9.1	(33.6)	(3.1)
Osphena [®]	4.6	2.2	2.0	89.3	2.0	(0.7)	(0.0)
Contract manufacturing	15.3	7.9	8.4	107.0	5.4	56.1	3.0
OTC and quasi-drugs	7.5	3.4	3.4	98.1	3.4	(1.5)	(0.1)
Royalty income	145.0	62.3	73.8	118.5	50.6	45.7	23.2
Royalty income for the sales of HIV franchise and Crestor $^{\ensuremath{\mathbb{R}}}$	125.0	56.4	57.6	102.1	46.0	25.2	11.6
HIV franchise	103.0	45.4	46.2	101.8	28.6	61.3	17.6
Crestor®	22.0	11.0	11.4	103.3	17.3	(34.4)	(6.0)
Others	2.9	1.4	1.2	86.4	1.2	1.2	0.0
Total	340.0	162.5	172.2	106.0	155.1	11.0	17.1



* The consolidated earnings forecasts announced on May 10, 2017 were written here, and the revisions to the forecasts were announced on Oct. 23, 2017.

Y on Y Comparison and Main Variation Factors (Sales by Segments)





* Payments both for development progression events (such as study initiation/phase progression) and for obtaining successful results ** Excluding received payments* from Roche

New Business Scheme with Roche for S-033188^e

Negotiated with Roche after obtaining positive results of OwH* study

Revised the original financial scheme to a new one, with a milestone structure that includes payments both for development progression events and for obtaining successful results More stable financial scheme for both companies which comprehensively takes into consideration the impacts to the fiscal period of each company

 In this 1H, Shionogi received the first payment (ca. 10.0 B yen) from Roche ahead of schedule



Maximizing the value of S-033188 globally through a stronger collaboration with Roche



Sales of Prescription Drugs in Japan


S-O-N-G for you!

						(Unit:	B yen)
		FY2	017		FY2016	Υο	n Y
	Full year Forecasts	1H Forecasts*	1H Results	Progress vs. 1H forecasts (%)	1H Results	Change (%)	Change (B yen)
Cymbalta [®]	25.3	11.1	11.7	105.5	8.9	31.8	2.8
Intuniv [®]	0.62	0.29	0.69	238.2	-	-	0.69
Symproic [®]	0.38	0.08	0.16	203.6	-	-	0.16
Total of Strategic products	26.3	11.5	12.6	109.5	8.9	41.4	3.7
Actair [®]	0.13	0.05	0.05	111.8	0.03	82.4	0.02
Mulpleta [®]	0.17	0.08	0.08	99.7	0.06	38.1	0.02
Pirespa®	6.0	3.1	3.1	101.7	3.0	3.3	0.10
OxyContin [®] franchise	8.9	4.6	4.6	98.0	5.0	(9.3)	(0.47)
Rapiacta [®]	2.8	0.14	0.07	52.5	0.12	(39.2)	(0.05)
Brightpoc [®] Flu	0.93	0.09	0.14	145.6	0.09	44.3	0.04
Glashvista [®]	0.69	0.34	0.15	42.7	0.41	(64.8)	(0.27)
Total of New Products	45.8	19.9	20.7	104.2	17.6	17.5	3.1
Crestor [®]	36.4	24.7	22.0	89.1	21.9	0.2	0.04
Irbetan [®] franchise	14.8	7.6	7.8	102.1	7.8	(0.6)	(0.05)
Others	46.9	23.0	22.7	98.6	31.8	(28.6)	(9.1)
Prescription drugs	143.9	75.2	73.2	97.3	79.2	(7.6)	(6.0)



* The consolidated earnings forecasts announced on May 10, 2017 were written here, and the revisions to the forecasts were announced on Oct. 23, 2017.

Y on Y Comparison and Main Variation Factors (Sales of Prescription Drugs in Japan)





*Other New Products: Actair[®], Mulpleta[®], Pirespa[®], OxyContin[®] franchise, Rapiacta[®], Brightpoc[®] Flu, and Glashvista[®] ** The consolidated earnings forecasts announced on May 10, 2017 were written here, and the revisions were announced on Oct. 23, 2017. **13**

Sales Expansion of New Drugs and Negative Impact song of First Generic Entries for our Main Products


(Unit: B yen)

14

New drugs	Full year Forecast	1H Forecast*	1H Results
Growth of new drugs including Cymbalta®	+6.7	+2.2	+3.1
Launch of generics for Crestor [®] and Irbetan [®]	(7.2)	+2.5	(0.0)
Long-listed drugs, etc.	Full year Forecast	1H Forecast*	1H Results
Decreased sales of long-listed drugs including Flomox [®] Decreased stockpiling of Rapiacta [®]	(8.7)	(5.0)	(5.3)
Transferring the marketing rights for long-listed 24 drugs	(4.9)	(3.8)	(3.8)
Prescription drugs	(14.1)	(4.0)	(6.0)

- New Products: Sales growth led by strategic products
- Crestor[®]: Lower than our forecast due to early uptake of Crestor[®] AG
- Long-listed drugs: On track

Sales Growth of New Products




S-0-N-G

for you!

** The consolidated earnings forecasts announced on May 10, 2017 were written here, and the revisions were announced on Oct. 23, 2017.

Progress in 1H FY2017*





*Change from April 1, 2016 to October 30 is only described PDPS: Peptide discovery platform system DTG: Dolutegravir RPV: Rilpivirine 16

S-O-N-G

for you!



1. 1st Half FY2017 Financial Results and FY2017 Financial Forecasts

1. 1st Half FY2017 Financial Results

2. FY2017 Financial Forecasts



Cited from presentation material of FY2016 Financial Results Change and Basic Strategy in FY2017

Shionogi's Business Environment Change in FY2017

- Sales in Japan
 - Launches of generic versions of Crestor[®] and Irbetan[®]
 - Some reduction in sales since the marketing rights for long-listed drugs have been transferred

Cost of sales

- No immediate advantage from reduction in sales of long-listed drugs

Royalty income

Reduced royalty income from Crestor[®] from AstraZeneca

Total Cost

– Increase in pre-launch and marketing costs related to launch of multiple new products

Basic Strategy in FY2017

- While flexibly responding to a challenging business environment, achieve revenue and profit targets by *strengthening and enhancing the growth trajectory of new products*
- Continue to make strong progress in global R&D to advance new growth drivers and maintain sustainable growth



Shionogi's Business Environment in 2H FY2017

Sales in Japan

- Crestor[®]: Lower than our forecast due to launch of Crestor[®] generics
- Oxycodone: Approval of tamper resistant formulation
- S-033188: NDA submission under Sakigake fast-track review*

Overseas Business

- Osphena[®]: Completion of vaginal dryness study
- Symproic[®]: Launch in US (Oct. 12, 2017)
- Lusutrombopag: Rolling submission of NDA in US (first part Sep. 25, 2017)

Total Cost

- New Financial Scheme with Roche on S-033188
 - > Received the first payment (ca. 10.0 B yen) from Roche ahead of schedule



Key Actions in Response to Shionogi's Business Environmental Changes in 2H FY2017 -1-

Sales in Japan

- Maintaining sales growth of new products
 - > Cymbalta[®]: Maximizing the value in the pain area
 - > Intuniv[®]: Providing more information of ADHD and Intuniv[®] to support further uptake
 - > Oxycontin[®] family: Preparation for launch of tamper resistant formulation
- Maximizing the value of our anti-flu drugs
 - > S-033188: Preparation for launch
 - > Rapiacta[®]: Collecting efficacy and safety data in repeat-dose study of patients with underlying respiratory disease

Overseas Business

- Osphena[®]: Maximizing the value of Osphena[®] in collaboration with Duchesnay Inc. and preparation for the NDA for vaginal dryness to FDA
- Symproic[®]: Collaboration with Purdue Pharma L.P. for a smooth launch
- Developing the marketing strategy to maximize the value of cefiderocol and lusutrombopag in hospital/highly-specialized markets




Key Actions in Response to Shionogi's Business Environmental Changes in 2H FY2017 -2-

Cost Management

 Shionogi will reinvest the payment* from Roche which was obtained as the result of our proactive investment in the global Phase III study of the highest priority compound S-033188 for further revenue and profit growth

> Accelerate R&D for growth drivers, including S-033188

⇒ Taking actions for further profit growth in addition to achieving the targets for our basic business





* Payments both for development progression events (such as study initiation/phase progression) and for obtaining successful results

Upward Revision of FY2017 Financial Forecasts (Consolidated)



(Unit: B yen)

		FY2017			<u> </u>	n Y
	Original Forecast	Revised Forecast	Change	Full year Results	Change (%)	Change (B yen)
Sales	340.0	345.0	5.0	338.9	1.8	6.1
Operating income	112.5	113.5	1.0	108.2	4.9	5.3
Ordinary income	123.5	132.0	8.5	123.0	7.3	9.0
Profit attributable to owners of parent	92.0	101.0	9.0	83.9	20.4	17.1


 Upward revisions for all categories of income and profit 	Exchange Rate (average)	FY2017 Forecasts	FY2016 Results
First time for Shionogi to	USD (\$) – JPY (¥)	110.0	108.39
exceed the profit attributable to owners of parent of 100.0	GBP (£) – JPY (¥)	140.0	141.62
billion yen	EUR (€) – JPY (¥)	120.0	118.80



1H Results and Revised Full Year Forecasts of FY2017

S-O-N-G

23



* Payments both for development progression events (such as study initiation/phase progression) and for obtaining successful results ** The consolidated earnings forecasts announced on May 10, 2017 were written here, and the revisions were announced on Oct. 23, 2017.

SHIONOGI

Revision of Statement of Income (Consolidated)



		FY2017		FY2016	Υo	n Y	(Unit: B yer
	Original Forecast	Revised Forecast	Change	Full year Results	Change (%)	Change (B yen)	
Sales	340.0	345.0	5.0	338.9	1.8	6.1	
(Royalty [*] income)	125.0	125.8	0.8	106.3	18.3	19.5	
	22.5 [35.6]	22.2 [34.9]		23.0 [33.4]			
Cost of sales	76.5	76.5	-	77.8	(1.6)	(1.3)	
Gross profit	263.5	268.5	5.0	261.1	2.8	7.4	-
SG&A expenses	44.4	44.9		45.1			
-	151.0	155.0	4.0	152.9	1.4	2.1	
Selling & administrative	29.1	29.0		27.5			-
expenses	99.0	100.0	1.0	93.0	7.5	7.0	
R&D expenses	^{15.3} 52.0	^{15.9} 55.0	3.0	^{17.7} 59.9	(8.2)	(4.9)	
Operating income	^{33.1} 112.5	^{32.9} 113.5	1.0	^{31.9} 108.2	4.9	5.3	-
Non-operating income & expenses	P11.0	P18.5	7.5	P14.9	24.6	3.6	-
Ordinary income	^{36.3} 123.5	^{38.3} 132.0	8.5	^{36.3} 123.0	7.3	9.0	-

Main 1. Selling & administrative expenses +1.0 B yen: Increase of expenses regarding C&O and SI

2. R&D expenses +3.0 B yen: Increase of expenses in the global Phase III study of S-033188

reasons 3. Increased dividend from ViiV +7.5 B yen: Global sales growth of HIV franchise

SHIONOGI

Note: The inside of [] is percentage of cost of sales to sales excluding royalty income * Royalty income from Viiv (HIV franchise) and Astra Zeneca (Crestor[®])

Revision of Sales by Segments (Consolidated)

S-O-N-G for you!

(Unit: B yen)

	FY2017		FY2016	Yo	n Y	
	Original Forecast	Revised Forecast	Change	Full year Results	Change (%)	Change (B yen)
Prescription drugs	143.9	144.1	0.2	158.0	(8.8)	(13.9)
Overseas	25.4	25.5	0.1	29.2	(12.7)	(3.7)
Shionogi Inc.	12.0	11.2	(0.8)	17.9	(37.3)	(6.7)
Osphena®	4.6	3.9	(0.7)	4.7	(17.8)	(0.8)
Contract manufacturing	15.3	15.4	0.1	12.1	27.0	3.3
OTC and quasi-drugs	7.5	7.0	(0.5)	6.8	3.1	0.2
Royalty income	145.0	150.3	5.3	115.7	30.0	34.7
Royalty income for the sales of HIV franchise and Crestor®	125.0	125.8	0.8	106.3	18.3	19.5
HIV franchise	103.0	103.3	0.3	73.3	40.9	30.0
Crestor®	22.0	22.5	0.5	33.0	(31.8)	(10.5)
Others	2.9	2.7	(0.2)	17.1	(84.4)	(14.4)
Total	340.0	345.0	5.0	338.9	1.8	6.1



Revision of Sales of Prescription Drugs in Japan

S-O-N-G for you!

(Unit: B yen)

		FY2017		FY2016	Υo	n Y
	Original Forecast	Revised Forecast	Change	Full year Results	Change (%)	Change (B yen)
Cymbalta [®]	25.3	26.0	0.6	19.0	36.5	6.9
Intuniv [®]	0.62	2.0	1.4	-	-	2.0
Symproic [®]	0.38	0.60	0.22	-	-	0.6
Total of Strategic products	26.3	28.6	2.3	19.0	50.3	9.6
Actair [®]	0.13	0.13	(0.0)	0.08	66.7	0.1
Mulpleta [®]	0.17	0.17	0.0	0.13	32.2	0.0
Pirespa [®]	6.0	6.0	(0.0)	5.8	2.0	0.1
OxyContin [®] franchise	8.9	8.9	0.0	9.7	(8.1)	(0.8)
Rapiacta®	2.8	2.8	0.0	2.9	(3.2)	(0.1)
Brightpoc [®] Flu	0.93	0.92	(0.0)	1.0	(6.6)	(0.1)
Glashvista [®]	0.69	0.31	(0.4)	0.55	(43.9)	(0.2)
Total of New Products	45.8	47.7	1.9	39.1	22.0	8.6
Crestor [®]	36.4	34.4	(2.0)	43.1	(20.2)	(8.7)
Irbetan [®] franchise	14.8	14.8	0.0	15.3	(3.1)	(0.5)
Others	46.9	47.2	0.3	60.5	(22.0)	(13.3)
Prescription drugs	143.9	144.1	0.2	158.0	(8.8)	(13.9)



Sales of Prescription Drugs in Japan (Revised)

Main variation factors in sales of prescription drugs in Japan


New drugs	1H Results	2H Revised Forecast	Full year Revised Forecast	(Unit: Byen)
Growth of new drugs including Cymbalta®	+3.1	+5.5	+8.6	
Launch of generics for Crestor [®] and Irbetan [®]	(0.0)	△9.2	△9.2	
Long-listed drugs, etc.	1H Results	2H Revised Forecast	Full year Revised Forecast	
Decreased sales of long-listed drugs including Flomox [®] Decreased stockpiling of Rapiacta [®]	△5.3	△3.1	△8.4	
Transferring the marketing rights for 24 long-listed drugs	△3.8	△1.2	△4.9	
Prescription drugs	△6.0	△7.9	△13.9	

- Decreased sales of Crestor[®] and Irbetan[®] due to the launch of generic drugs will be compensated for by the growth of new drugs including Cymbalta[®], Intuniv[®], Symproic[®], etc.
- Continue to focus on new drugs, not depending on the long-listed drugs



Objectives for 2H FY2017*







*Only describes changes since October 31, 2017 **BE: Bioequivalence




2. Maximizing Growth Drivers to Address Societal Needs -Contributing to a more vigorous society-

- 1. Growth Drivers Providing Revenue Base
 - HIV franchise
- 2. Next Growth Drivers
 - S-033188 and cefiderocol
 - Cymbalta[®] and ADHD franchise



Growth and Progress of HIV Franchise






- DTG/RPV: NDA submission in US and EU in Jun. 2017
 - Expected approval by the end of 2017



S-O-N-G

for you!

S-033188: Results for OwH study -1-



Stronger antiviral effect against influenza virus compared to oseltamivir

Time to cessation of viral shedding

S-O-N-G

for you!

 $(Age \ge 20)$

eddi	1.0]		- S-033188	
She	0.8				Oseltamivir	
iral				+	Censor	
in <	0.6					
nts		-				
atie	0.4					
of P						
on	0.2					
0.6 0.7 0.6 0.6 0.6 0.6 0.7 0.6 0.7 0.6 0.7 0.6 0.7 0.6 0.7 0.6 0.7 0.6 0.7 0.6 0.7 0.6 0.7 0.7 0.6 0.7 0.6 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7 1 0.7 1 1 1 1 1 1 1 1					,	
0 30 60 90 120 150 180 210 240						
			Time from	Start of Treatmen	it (hours)	
				S-033188	Oseltamivir	
				N=348	N=355	
Median (95% CI), hours		24.0	72.0			
		(24.0, 48.0)	(72.0,96.0)			
Difference vs placebo		-48.0				
(95% CI ^[***]), hours		(-72.0, -24.0)				
Stratified Generalized						
Wilcoxon test vs Oseltamivir		0001				
p-value				< .0001		


*** Bootstrap estimates

*Modified from the presentation material at IDWeek[™] 2017



S-033188: Results for OwH study -2-

Proportion of Patients Positive for Influenza Virus Titer(%)



- S-033188 showed a strong antiviral effect against influenza virus
- From the day after taking medicine, proportion of patients positive for influenza virus titer significantly decreased compared to oseltamivir



S-O-N-G

for you!

S-033188: Rapid NDA Submission to Address Societal Needs

NDA submission under Sakigake fast-track review* (Oct. 25, 2017)

- Generic name: baloxavir marboxil
- Assured adherence
 - Stronger antiviral effect and safer profile compared to oseltamivir
 - Only a single oral dose both for adults and children
- Expected to suppressing virus transmission and general aerosolmediated infection in households, schools or workplaces

Addressing future flu pandemics

 Strong antiviral effect against various influenza subtypes including avian influenza (H5N1 or H7N9) and viruses resistant to existing antiflu drugs



Accelerating global development by strengthening collaboration with Roche



Cefiderocol: Multidrug-resistant Gramnegative bacterial infections



Threat of AMR (Antimicrobial Resistance)

- Impact of AMR by 2050*
 - The number of deaths is estimated to be over 10 million globally
 - Impact on GDP is estimated to be \$100 trillion
- Cefiderocol is receiving global attention as a drug candidate to treat infections caused by all three bacteria classified as critical priority by WHO
 - Pseudomonas aeruginosa, Acinetobacter baumannii, and Enterobacteriaceae
- R&D for new anti-microbial agents is supported globally
 - Generating Antibiotics Incentives Now Act (GAIN Act) in US

Global Development of Cefiderocol

- Preparation of NDA submission for cUTI in US
 - Cefiderocol is designated as *QIDP* by FDA in US
 - > Priority review and fast track designation
 - > Extension of patent/marketing exclusivity will be given after approval
- Two global phase III studies are ongoing
 - (1) Carbapenem-resistant study (2) HAP/VAP study

Cymbalta[®]: Pediatric Study for Cymbalta[®]

Jul. 2016 Therapeutic guidelines were revised and recommended appropriate treatment by antidepressants in the US




- Jul. 2016 Therapeutic guidelines of the Japan Society of Mood Disorders (2nd Edition) were published
- Rising medical need for treatment of pediatric depression with medicines
- → No medicines indicated for treatment of depression and depressive symptoms in children in Japan
- → Shionogi began clinical trials of Cymbalta[®] to determine optimal dosage and administration for children and adolescent use (Jul. 2017)
- \rightarrow Reexamination period of Cymbalta[®] was extended (Aug. 2017)



S-O-N-G


Trend of ADHD Market in Japan



Sales are increasing 30% or more* annually

S-O-N-G

for you!






Source: JAMMNET Data

 $\left(\frac{\text{Sales forfiscal n year}}{\text{Sales for fiscal 2010}}\right)^{\frac{1}{n-1}} - 1$ 36

Intuniv[®]: Phase III Study in Adults



- First positive results of Intuniv[®] in adult patients in the world
- Continue to accumulate long-term efficacy and safety data
- Targeting approval of additional indication for adult ADHD in FY2019

			Baseline	Week10				
	Treatment Group	Obs	served Value	Oł	oserved Value	Change from baseline	vs Placebo	
		n	Mean (SD)	n	Mean (SD)	LS Mean (SE)	Difference of LS Mean [95% CI]	p-value
ſ	Placebo	100	31.70 (6.83)	93	23.55 (10.29)	-7.27 (1.07)		
	Intuniv®	100	31.45 (5.92)	79	19.53 (9.45)	-11.55 (1.10)	-4.28 [-6.67, -1.88]	0.0005




S-O-N-G



3. Addressing Further Societal Needs to Achieve Sustainable Growth



Ś.O.N.G **History and Future Perspective of Medicine**



SHIONOGI

39 *Modified from the presentation material of PeptiDream Inc.

Balancing Innovation and Health Economics

	Small Molecules	Specific Peptides	Antibodies
Molecular weight	-500	500 - 2,000	ca. 150,000
Specificity	Mid – High	High	High
Side effect	Low - Mid	Low	Low
Intracellular target	Achievable	Achievable	Not achievable
Manufacturing costs	Low	Low	High
Oral dosing	Easy	Possible	Difficult

X

Innovation

Drug discovery for intracellular targets which can not be reached by antibodies

Health economics

Low cost manufacturing allows flexibility to meet health economic demands



History of Shionogi's Peptide Drug Discovery

Utilizing our know-how in small molecule drug discovery and manufacturing of proteins/peptides to meet medical needs

- In 1990: Launch of Immunomax [®]-γ (protein drug)
- In 1992: Launch of Immunase[®] (protein drug)
- R&D derived from protein or peptide: NS75A/NS75B (GnRH* antagonist), S-0373 (TRH** mimetic non-peptide compound), etc.
- In 2017: Several drug candidates of peptide or nucleic acid in our pipeline


Preclinical	Phase I	Phase II	Phase III
Peptide candidate	Global	S-488210 Head and neck squamous cell carcinoma	
Botulinum toxin candidate		S-588410 Bladder cancer	
Nucleic acid candidate	In Japan	S-588410 Bladder cancer	S-588410 Esophageal cancer



Improving Productivity with New Platforms

Grow sustainably as a drug discovery-based pharmaceutical company beyond 2020

Activating drug discovery process by strengthening technology platforms to allow us to sustainably generate development candidates with high productivity



SHIONOGI

Collaboration with PeptiDream Inc.

1. Feb. 5, 2016: Research collaboration for 4 targets

 → Achieved its first milestone in Mar. 2017 (Obtained a high-activity hit peptide)

2. Jun. 12, 2017: Non-exclusive license for PDPS*

- The first Japanese company to in-license PDPS* technology
- The productivity of drug discovery can be dramatically improved by widely utilizing this technology together with Shionogi's small molecular drug discovery capability
- 3. Sep. 1, 2017: Established a new CMO (PeptiStar) DeptiStar
 - R&D, manufacturing, sales and marketing for API** of specific peptides








S-O-N-G

Ongoing Collaborative Research with PeptiDream Inc.





S-O-N-G for you!

Collaboration with UMN Pharma

About UMN Pharma

- Company Name: UMN Pharma Inc.
 - Incorporated in 2004 as a pharmaceutical venture targeting for Unmet Medical Needs
 - Listed on the Tokyo Stock Exchange MOTHERS market in 2012
- Paid in capital: 217 million yen (As of Sep. 30, 2017)
- Location: Yokohama Headquarters, Yokohama Research Center, Akita Laboratory, Akita Manufacturing Facilities
- Employees : 23 including 16 researchers (As of Sep. 30, 2017)
- Main Business: Cutting-edge original vaccine manufacturing platform
 - 1. R&D of next generation biomolecules (mainly various anti-infectious disease vaccines)
 - Seasonal Influenza vaccine (UMN-0502)
 - Norovirus VLP* single vaccine (UMN-2002)
 - Rotavirus VLP* single vaccine (UMN-2001), etc.
 - 2. Contract manufacturing of biopharmaceuticals (early to mid stage of development)



S-0-N-G

Significance of the Collaboration with UMN Pharma



Significance and expected outputs from the collaboration

UMN Pharma: Strengths and features

- Platform to manufacture recombinant protein antigens which will be the core of next-generation vaccines
- Development of anti-infective vaccines
- R&D facilities covering early to mid stage of development

- Shionogi: Strengths and features
 - R&D for infectious diseases
 - R&D of small to mid sized molecules
 - Focused on development of novel drug discovery platforms
 - Development of in-house adjuvants

Synergy: UMN's vaccine platform meets Shionogi's strategy for infectious diseases

- Acquiring new strengths for influenza, RSV*, herpes viruses, norovirus etc.
- Synergistic benefit by applying our in-house adjuvants
- Addressing emerging and re-emerging infectious diseases
- Funding scheme**
 - 3rd party allocation: c.a. 170 million yen
 - Convertible bonds: c.a. 1.43 billion yen
 - Certain milestone payments

Short term goals

- Establishment of basic technology platform supporting future global business
- Securing manufacturing facilities for commercial protein drugs
- Mid-Long term goals
 - Expanding our product lineup from prevention to treatment
 - Strengthening infectious disease pipeline



* Respiratory syncytial virus (RSV): one of RNA viruses

** Estimated price from closing stock price of 288 yen (as of Sep. 22, 2017)




Shareholder Return





	Divi	dend per sh	DOE	ROE	
	half-year	year-end	annual		KUE
FY2016	34.00	38.00	72.00	4.5%	16.3%
FY2017	38.00	(Plan) 38.00	(Plan) 76.00	(Estimate) 4.3%	(Estimate) 17.8%

Planning continuous increases in both half-year dividends and annual dividends








Appendix

- Shareholder Return
- Pipeline
- Target Milestones for Launch of New Products
- S-033188: Summary for OwH study
- Activities of the Office for Children's Bright Future



Shareholder Return Policy of Shionogi

- Maximize enterprise value by balancing three key factors: return to shareholders, investment for further growth and strategic opportunities
- Sharing our mid- to long-term profit growth with our shareholders by increasing returns as appropriate by share buyback, cancellation of treasury stocks, and elimination of cross-share holdings





S-O-N-G

Target Milestones for FY2017 (as of Oct. 2017)




Areas	Product	As of Apr. 1, 2017	Target for FY2017
Infectious	Cefiderocol Multidrug-resistant Gram-negative bacterial infections	Global: Preparation for NDA submission	US: NDA submission
disease	S-033188 (baloxavir marboxil) Influenza virus infection	Global: Japan: Phase III Phase III (pediatric)	Japan: NDA submission
	Intuniv[®] ADHD (pediatric)	Japan: NDA submission	Japan: Launch
	Symproic [®] Opioid-induced constipation	Japan: Approval	Japan: Launch
	Symproic [®] Opioid-induced constipation	US: Approval	US: Launch
Pain/CNS	Oxycodone Treatment of moderate to severe chronic pain	Japan: NDA submission	Japan: Approval
	Oxycodone Tamper resistant formulation	Japan: NDA submission	Japan: Approval
	Lisdexamfetamine ADHD (pediatric)	Japan: Preparation for NDA submission	Japan: NDA submission
	Cymbalta[®] Depression (pediatric)	-	Japan: Phase III
	S-600918 Neuropathic pain	Japan: Phase I	Phase II (regions to be determined)
Frontier	Lusutrombopag Thrombocytopenia associated with chronic liver disease	Global: Phase III	US and EU: NDA submission
riolitier	Actair® (Pediatric allergic rhinitis caused by house-dust mite allergen	Japan: NDA submission	Japan: Approval



Red frame: Change since August 1 2017 ADHD: Attention deficit hyperactivity disorder

Pipeline (as of Oct. 2017)







Target Milestones for Launch of New Products




FY2017	FY2018	FY2019			
Japanese business					
Symproic [®] Intuniv [®] ADHD (pediatric) Oxycodone Tamper resistant formulation Actair [®] Pediatric patients with perennial allergic rhinitis	S-033188 (baloxavir marboxil) Lisdexamfetamine	Intuniv® ADHD (adult)			
Overseas business	·	•			
Symproic [®] (US)	Cefiderocol Osphena [®] Vaginal dryness associated with postmenopausal VVA Lusutrombopag Naldemedine (EU)				
Global out-licensed products					
	DTG + RPV	DTG + 3TC			



Cited from presentation material of 1Q FY2017 Financial Results

S-033188: Summary for OwH study

- Time to alleviation of symptoms (TTAS)
 - S-033188 demonstrated a statistically significant reduction in TTAS compared to placebo and achieved the primary objective.
- Viral titer
 - S-033188 demonstrated statistically significant differences, in the early post-treatment period, both in the reduction of virus titer, and in the duration of viral shedding, compared to either placebo or oseltamivir.
- Safety
 - S-033188 was well tolerated. The incidence of treatment-related adverse events in the S-033188 treatment arm was comparable to that in the placebo arm.
 - The S-033188 treatment arm had statistically significantly fewer treatment-related adverse events compared to the oseltamivir arm.



Activities of the Office for Children's Bright Future

Aiming to create vigorous society: *Providing patients with developmental disabilities and/or central nervous system diseases with life-improving support*





S-O-N-G





Partnership with Osaka Prefectural Government
 Sponsorship with Hyogo prefecture's event of World Autism Awareness Day
 Blue Lighting of Osaka Castle on World Autism Awareness Day (Photo 1)
 Co-sponsored Symposium on Developmental Disorders (Photo 2)
 Ind 9 Training program for child care workers and kindergarten teachers
 Medicines Lab (hands-on learning: tablet making and dissolution of drug)
 for children to understand contribution of medicines to better health
 Lecture on work strategies of persons with hearing difficulties in special
 support schools
 Introduction to Parents Program



Forward-Looking Statements

- Forecast or target figures in this material are neither official forecasts of earnings and dividends nor guarantee of target, achievement and forecasts, but present the midterm strategies, goals and visions. Official earnings guidance should be referred to in the disclosure of the annual financial report (*kessan tanshin*) in accordance with the rules set by Tokyo Stock Exchange.
- Materials and information provided during this presentation may contain so-called "forward-looking statements". These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties which could cause actual outcomes and results to differ materially from these statements.
- Risks and uncertainties include general industry and market conditions, and general domestic and international economic conditions such as interest rate and currency exchange fluctuations. Risks and uncertainties particularly apply with respect to product-related forward-looking statements. Product risks and uncertainties include, but are not limited to, technological advances and patents attained by competitors; challenges inherent in new product development, including completion of clinical trials; claims and concerns about product safety and efficacy; regulatory agency's examination period, obtaining regulatory approvals; domestic and foreign healthcare reforms; trend toward managed care and healthcare cost containment; and governmental laws and regulations affecting domestic and foreign operations.
- For products that are approved, there are manufacturing and marketing risks and uncertainties, which include, but are not limited to, inability to build production capacity to meet demand, unavailability of raw materials, and failure to gain market acceptance.
- Shionogi disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.
- This material is presented to inform stakeholders of the views of Shionogi's management but should not be relied on solely in making investment and other decisions.
- You should rely on your own independent examination of us before investing in any securities issued by our company. Shionogi shall accept no responsibility or liability for damage or loss caused by any error, inaccuracy, misunderstanding or changes of target figures or any other use of this material.
- This English presentation was translated from the original Japanese version. In the event of any inconsistency between the statements in the two versions, the statements in the Japanese version shall prevail.



S-O-N-G